Moberg Pharma reports positive interim results in phase II clinical study of MOB-015

Moberg Pharma AB (OMX: MOB) today announced positive interim results from its
ongoing phase ll study of MOB-015. After six months of treatment with MOB-015,
40 per cent of the patients were mycologically cured and no safety concerns were
identified. MOB-015 is a novel topical formulation of terbinafine for the
treatment of nail fungus (onychomycosis).
The purpose of the study is to confirm the product concept of MOB-015 and
provide a basis for out-licensing and further clinical development. 25 patients
will be treated for twelve months and followed for a total of fifteen months
with respect to the endpoints that the FDA and EMA normally accept for nail
fungus. The primary endpoint is the proportion of patients with mycological
cure, defined as negative culture and negative KOH microscopy. The study is
conducted with leading expertise in the field at Sahlgrenska University Hospital
in Gothenburg, Sweden. Patient enrollment in the study was completed in May 2013
and the final results are expected second half of 2014.

"These 6-month interim data are clearly promising and indicate very competitive
performance of MOB-015", said Kjell Rensfeldt, VP R&D at Moberg Pharma.

"We are excited to announce the interim data for MOB-015. Oral terbinafine is
the gold standard for the treatment of nail fungus. If the final data follow the
trajectory of the interim results for this novel topical formulation, MOB-015
has the potential to become a major advance in the treatment of nail fungus",
said Peter Wolpert, CEO of Moberg Pharma.

The results from the interim analysis are no guarantee that the final results at
study completion will be positive.

About MOB-015 and nail fungus
MOB-015 is a new topical treatment for nail fungus. MOB-015 is based on Moberg
Pharma's patent pending formulation technology, which in preclinical studies has
been shown to transport high concentrations of terbinafine into and through nail
tissue. As MOB-015 is applied locally, the safety issues associated with oral
medications are avoided. Nail fungus is a common nail disease. It afflicts
approximately 10 percent of the population and is more common among the elderly.
The market is expected to exceed USD 1 billion. Many patients remain untreated
and according to specialists in the field, there is a great need for a new
topical treatment with a favorable safety profile.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.00 am (CET) on December 13, 2013.
For further information, please contact:
Peter Wolpert, CEO
Mobile: +46 (0)70 - 735 71 35; E-mail:
peter.wolpert@mobergpharma.se (peter.wolpert@mobergderma.se)

Peter Östling, IR
Mobile: +46 (0)76 - 314 09 78; E-mail: peter.ostling@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical company with
direct sales through its own sales organization in the US and sales through
distributors in more than 40 countries. The company’s product portfolio includes
topical products for the treatment of skin disorders and pain under the brands
Kerasal®, Jointflex®, Kerasal Nail™ and Kaprolac®. Kerasal Nail™ (Nalox™ in many
markets) is the leading product for the treatment of nail disorders in the
Nordic market. The portfolio is developed further through acquisitions and in
-licensing of products as well as product development with focus on innovative
drug delivery based on proven compounds. Moberg Pharma has offices in Stockholm
and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap
list of the NASDAQ OMX Nordic Exchange Stockholm. For further information,
please visit: www.mobergpharma.com.